• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Gastrointestinal Endoscopy >Neoadjuvant therapy with imatinib mesylate for locally advanced GI stromal tumor.
【24h】

Neoadjuvant therapy with imatinib mesylate for locally advanced GI stromal tumor.

机译：甲磺酸伊马替尼的新辅助疗法用于局部晚期胃肠道间质瘤。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

GI stromal tumors (GIST) are mesenchymal neoplasms that arise from precursors of connective tissue cells of the GI tract and that appear to be related to the interstitial Cajal's cells of the myenteric plexus. Although the true incidence is unknown, it is estimated that as many as 5000 to 6000 cases occur in the United States annually. GISTs can arise at any location in the GI tract and have in common the expression of the c-kit proto-oncogene protein, a cell-surface transmembrane receptor with tyrosine kinase activity that leads to uncontrolled cell proliferation and resistance to apoptosis. The primary therapy for resectable GISTs remains surgery. Until recently, there has been no effective therapy for unresectable or metastatic GISTs. Treatment of advanced GISTs with imatinib mesylate, also known as STI571 (Gleevec; Novartis Pharmaceuticals, Basel, Switzerland), a selective inhibitor of certain tyrosine kinases (including c-kit), has achieved partial responses, with substantial reductions in tumor bulk in over half of patients. These dramatic decreases' in tumor size make the prospect of using imatinib mesylate in the adjuvant or the neoadjuvant setting intriguing. A case is described in which imatinib mesylate was used before surgery to facilitate the subsequent surgical resection of a locally advanced rectal GIST.
机译：胃肠道间质瘤（GIST）是由胃肠道结缔组织细胞的前体产生的间质肿瘤，似乎与肌间神经丛的间质Cajal细胞有关。尽管真实的发病率未知，但据估计在美国每年发生多达5000至6000例。 GIST可以出现在胃肠道的任何位置，并共同表达c-kit原癌基因蛋白，这是一种具有酪氨酸激酶活性的细胞表面跨膜受体，可导致不受控制的细胞增殖和抗凋亡作用。可切除的GIST的主要疗法仍然是手术。直到最近，还没有针对无法切除或转移的GIST的有效疗法。甲磺酸伊马替尼也被称为STI571（Gleevec; Novartis Pharmaceuticals，Basel，Switzerland），一种酪氨酸激酶（包括c-kit）的选择性抑制剂，对晚期GIST的治疗已获得部分缓解，并且在2000到2000年间肿瘤体积大大减少一半的病人。肿瘤大小的这些显着减小使人们对在辅助剂或新辅助剂中使用甲磺酸伊马替尼的前景产生兴趣。描述了一个病例，其中在手术前使用甲磺酸伊马替尼以利于后续手术切除局部晚期直肠GIST。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号